1. Why Dissolution and Solubility Matter in PBPK
For an orally administered drug, systemic exposure begins with a sequence of events in the gastrointestinal tract. The dosage form must release drug, solid drug must dissolve into gastrointestinal fluid, dissolved drug must remain available for absorption, and the drug must cross the intestinal barrier before reaching the systemic circulation.
Solubility describes how much drug can be present in solution under specified conditions. Dissolution describes the rate at which solid drug enters solution. These are related but distinct properties.
A mechanistic absorption model can connect formulation properties and gastrointestinal physiology to the dissolved drug available for intestinal absorption.
2. What Is Drug Solubility?
Solubility is the equilibrium amount of a substance that can dissolve in a specified solvent under specified conditions. For an orally administered drug, the relevant solvent is often gastrointestinal fluid, whose composition can change substantially along the GI tract.
Solubility is therefore not necessarily a single universal property of a molecule. It can depend on pH, temperature, ionic strength, bile components, buffer composition, solid form, and other environmental conditions.
For ionizable compounds, pH can have a particularly strong effect. A simplified relationship for a monoprotic weak acid can be expressed as:
For a monoprotic weak base:
Here, \(S_0\) represents intrinsic solubility of the neutral species. These equations illustrate why the same compound can have substantially different apparent solubility at different gastrointestinal pH values.
3. Solubility Is Not the Same as Dissolution
A drug can have adequate equilibrium solubility but dissolve slowly. Conversely, a formulation can dissolve rapidly initially but encounter a solubility limit that restricts the amount that can remain in solution.
A commonly used conceptual description of dissolution is the Noyes–Whitney relationship:
where \(M\) is the amount dissolved, \(A\) is the surface area of the dissolving particles, \(C_s\) is the saturation solubility, \(C\) is the bulk dissolved concentration, and \(k_d\) represents a mass-transfer term.
The equation shows two important drivers:
- Surface area: smaller particles generally provide greater surface area per unit mass and can increase dissolution rate.
- Concentration gradient: dissolution is faster when the bulk concentration is well below the saturation concentration.
In PBPK applications, dissolution models may be considerably more detailed than this simple representation. The objective is to describe the rate at which drug becomes available for absorption under physiologically changing conditions.
4. Why Particle Size and Surface Area Matter
For a given mass of drug, reducing particle size generally increases total surface area. Because dissolution occurs at the solid-liquid interface, this can increase the dissolution rate.
For a fixed mass of spherical particles, the number of particles increases rapidly as particle radius decreases. Consequently, the total surface area available for dissolution can increase substantially after micronization or other particle-size reduction processes.
| Formulation property | Potential effect on dissolution | PBPK relevance |
|---|---|---|
| Particle size | Changes available surface area | Can alter the dissolution time course |
| Solid-state form | Can change thermodynamic activity and solubility | May change both dissolution and available concentration |
| Wetting | Influences contact between solid particles and fluid | Can affect effective dissolution rate |
| Formulation excipients | May alter dispersion, wetting, or precipitation | Can modify drug availability for absorption |
| Particle aggregation | Can reduce effective surface area | May slow dissolution relative to nominal particle size |
Particle size should therefore be interpreted as one component of a broader formulation-dependent dissolution process rather than as an isolated predictor of exposure.
5. pH-Dependent Solubility Along the GI Tract
The gastrointestinal tract is not a single homogeneous compartment. Gastric and intestinal regions differ in pH, fluid volume, transit time, buffer capacity, bile composition, and other physiological characteristics.
The GI tract presents changing physicochemical and physiological conditions. PBPK models use these differences to represent regional drug dissolution and absorption.
For an ionizable drug, movement from the stomach to the intestine can therefore change the fraction of drug that is ionized and the amount that can remain dissolved.
This is one reason a single aqueous solubility measurement may not adequately describe oral absorption across the entire GI tract.
6. Solubility, Permeability, and the Biopharmaceutics Classification System
The Biopharmaceutics Classification System (BCS) organizes immediate-release drug products according to aqueous solubility and intestinal permeability.
| BCS class | Solubility | Permeability | General implication |
|---|---|---|---|
| Class I | High | High | Neither dissolution nor permeability is generally expected to be the dominant limitation under standard BCS conditions |
| Class II | Low | High | Dissolution and/or solubility can become important determinants of absorption |
| Class III | High | Low | Permeability can be an important limitation |
| Class IV | Low | Low | Both solubility and permeability can limit absorption |
BCS classification is useful for understanding broad biopharmaceutic behavior, but a PBPK model can represent considerably more detail. It can incorporate regional physiology, formulation properties, dissolution kinetics, precipitation, permeability, and metabolism.
7. Supersaturation and Precipitation
Some formulations can temporarily produce dissolved drug concentrations above the equilibrium solubility of the stable crystalline form. This condition is known as supersaturation.
Supersaturation can arise, for example, when a drug experiences a rapid change in pH or when a formulation produces an amorphous or otherwise higher-energy drug state.
The dissolved concentration may initially exceed the equilibrium solubility, followed by precipitation toward a lower-energy solid state.
The transient supersaturated concentration can be important because absorption can occur while the drug is supersaturated. Consequently, a formulation may provide greater absorption than would be predicted from equilibrium solubility alone if the supersaturated state persists long enough for substantial intestinal uptake.
PBPK models can represent this behavior through precipitation and re-dissolution mechanisms, allowing the model to distinguish between the initial dissolution process and the subsequent evolution of dissolved drug concentration.
8. How Formulation Can Change Dissolution
The same active pharmaceutical ingredient can exhibit different oral exposure depending on how it is formulated.
- Micronization: reducing particle size can increase surface area and dissolution rate.
- Amorphous formulations: a higher-energy solid state can provide greater apparent solubility but may introduce precipitation risk.
- Solid dispersions: polymers can help maintain drug in a dispersed or supersaturated state.
- Salt forms: changing the solid form can alter dissolution and apparent solubility.
- Lipid-based formulations: can change solubilization, dispersion, and precipitation behavior in GI fluids.
- Excipients: surfactants, polymers, and other formulation components can affect wetting, solubilization, and precipitation.
A PBPK model can use formulation-specific dissolution or precipitation parameters to translate these differences into predicted intestinal concentrations and systemic exposure.
9. From Dissolved Drug to Intestinal Absorption
Dissolution does not guarantee systemic absorption. Once drug is dissolved, it must remain available and cross the intestinal epithelial barrier.
A conceptual mass-balance relationship is:
where \(A_{\mathrm{diss}}\) is the amount of dissolved drug, \(R_{\mathrm{diss}}\) is the dissolution rate, \(R_{\mathrm{precip}}\) is the precipitation rate, and \(R_{\mathrm{abs}}\) is the absorption rate.
This equation illustrates the central PBPK concept: dissolved drug is a dynamic pool. Its size depends on competing processes rather than on dissolution alone.
10. How PBPK Models Represent Dissolution
A mechanistic PBPK absorption model typically divides the GI tract into physiologically meaningful regions. Drug can then move between regions while simultaneously undergoing dissolution, precipitation, degradation, and absorption.
A mechanistic absorption model tracks drug across solid, dissolved, and absorbed states while accounting for physiological and formulation-dependent processes.
The model may incorporate:
- GI fluid volumes and transit times.
- Regional pH and buffer conditions.
- Drug particle size and surface area.
- Intrinsic and pH-dependent solubility.
- Dissolution kinetics.
- Precipitation and re-dissolution.
- Intestinal permeability.
- Enterocyte metabolism and transport.
11. Common Dissolution Modeling Approaches
Different PBPK platforms use different implementations, but several conceptual approaches recur.
| Approach | Basic idea | When it can be useful |
|---|---|---|
| Instantaneous dissolution | Assumes drug becomes dissolved sufficiently rapidly relative to other processes | When dissolution is unlikely to limit absorption |
| Empirical dissolution profile | Uses observed dissolution data to define drug release into solution | When formulation-specific in vitro data are available |
| Mechanistic particle dissolution | Uses particle properties and mass-transfer relationships to predict dissolution | When formulation and physicochemical information are available |
| Solubility-limited model | Constrains dissolved concentration according to a solubility relationship | For compounds where aqueous solubility can limit absorption |
| Precipitation model | Allows supersaturated drug to return toward equilibrium through precipitation | For enabling formulations or pH-shift conditions |
The appropriate level of mechanistic detail depends on the scientific question, available data, and whether dissolution is expected to materially affect the exposure prediction.
12. Worked Example: A Poorly Soluble Oral Drug
Consider a hypothetical immediate-release oral drug with the following properties:
| Property | Value |
|---|---|
| Oral dose | 100 mg |
| Particle radius | 25 μm |
| Intrinsic solubility | 0.020 mg/mL |
| pKa | 7.0 |
| GI fluid pH | 6.0 |
| Initial intestinal dissolved volume | 250 mL |
Step 1: Estimate pH-dependent solubility
Assume the drug is a weak base. Using the simplified relationship:
Substituting \(S_0=0.020\) mg/mL, pH \(=6.0\), and pKa \(=7.0\):
Step 2: Estimate the equilibrium dissolved amount
Under these simplified conditions, approximately 5.5 mg could be present at equilibrium in 250 mL of fluid at the specified solubility.
Step 3: Interpret the result
The administered dose is 100 mg, whereas the simplified equilibrium dissolved amount is only 5.5 mg. This does not mean that only 5.5 mg can ever be absorbed. Gastrointestinal transit, changing volume, changing pH, precipitation, supersaturation, and continuous absorption all influence the dynamic system.
Instead, the calculation demonstrates why a poorly soluble compound may require a mechanistic dissolution and absorption model rather than an assumption of instantaneous and complete dissolution.
13. When Does Dissolution Become the Rate-Limiting Step?
Dissolution becomes particularly important when the drug's solid phase cannot supply dissolved drug rapidly enough to support the potential rate of intestinal absorption.
Conceptually:
By contrast, if dissolution is much faster than the rate at which dissolved drug can cross the intestinal membrane, permeability or another process may become more important.
| Potential limitation | Characteristic | Mechanistic consequence |
|---|---|---|
| Dissolution-limited | Solid drug enters solution slowly | Dissolved concentration may remain below the level needed to sustain maximal absorption |
| Solubility-limited | Equilibrium dissolved concentration is low | Absorption is constrained by the amount that can remain in solution |
| Permeability-limited | Dissolved drug crosses the intestinal barrier slowly | Increasing dissolution may have limited effect on exposure |
| Metabolism-limited | Drug is extensively metabolized before systemic entry | Systemic availability can remain low despite adequate dissolution |
14. How Food Can Change Dissolution and Solubility
Food can alter the gastrointestinal environment in several ways. Gastric emptying, fluid volume, pH, bile secretion, lipid content, and intestinal transit can all change following a meal.
For some compounds, food-associated bile components and lipids can increase solubilization. For others, changes in GI physiology can alter the timing or extent of dissolution and absorption.
A mechanistic PBPK model can represent these effects by changing physiological inputs and, where appropriate, drug-specific solubilization or precipitation behavior.
15. Why Dissolution Modeling Matters in Drug Development
Dissolution and solubility modeling can support formulation development and clinical pharmacology by connecting laboratory measurements with expected in vivo behavior.
- Comparing candidate formulations.
- Understanding the potential impact of particle-size reduction.
- Evaluating amorphous versus crystalline formulations.
- Investigating precipitation risk.
- Interpreting dissolution testing data.
- Exploring food effects.
- Supporting formulation changes during development.
- Evaluating dose proportionality when solubility may become limiting.
- Exploring exposure under different GI physiological conditions.
The key advantage is the ability to connect physicochemical properties → GI behavior → dissolved concentration → absorption → systemic exposure within a single mechanistic framework.
16. What Data Are Needed for a Dissolution PBPK Model?
The required data depend on how mechanistic the model is intended to be. Potential inputs include:
| Input | Examples | Role in the model |
|---|---|---|
| Solubility | Intrinsic solubility, pH-solubility profile | Defines equilibrium dissolved concentration |
| pKa | Acid/base ionization constants | Allows pH-dependent solubility to be represented |
| Particle properties | Size, density, shape assumptions | Influence dissolution rate |
| Solid-state properties | Polymorph, amorphous fraction | Can influence thermodynamic and kinetic behavior |
| Dissolution data | In vitro dissolution profiles | Can calibrate or validate dissolution behavior |
| Permeability | Experimental or estimated permeability | Controls intestinal uptake |
| GI physiology | pH, fluid volume, transit | Defines the in vivo environment |
| Formulation information | Excipients, release mechanism, dosage form | Defines formulation-dependent behavior |
Not every project requires every input. The objective is to use enough mechanistic information to answer the question without introducing parameters that cannot be adequately supported.
17. Evaluating a Dissolution PBPK Model
A dissolution PBPK model should be evaluated against observations relevant to the processes it is intended to represent.
- Check physicochemical inputs. Confirm that solubility, pKa, solid-state, and formulation assumptions are internally consistent.
- Evaluate dissolution behavior. Compare predicted and observed dissolution where appropriate.
- Examine intestinal concentrations. Determine whether the predicted dissolved concentration profile is plausible.
- Compare systemic PK. Evaluate predicted and observed Cmax, AUC, Tmax, and concentration-time profiles.
- Assess formulation differences. Test whether the model reproduces meaningful changes across formulations.
- Perform sensitivity analysis. Identify whether predictions depend strongly on uncertain dissolution or solubility parameters.
- Evaluate extrapolation. Distinguish predictions supported by data from predictions driven primarily by assumptions.
18. Which Parameters Matter Most?
Sensitivity analysis can reveal whether oral exposure is strongly influenced by dissolution and solubility parameters.
For example, a model might vary:
- Intrinsic solubility.
- Particle size.
- Dissolution rate constant.
- Precipitation rate.
- Permeability.
- GI transit time.
- Gastric emptying rate.
- Intestinal fluid volume.
If large changes in dissolution parameters produce little change in AUC or Cmax, dissolution may not be a major determinant under those conditions. If small changes produce substantial exposure changes, better characterization of the dissolution process may be important.
Sensitivity analysis therefore helps prioritize experimental work and identify which assumptions are consequential for the clinical prediction.
19. A Practical Workflow for Dissolution PBPK Modeling
- Define the question. Are you investigating formulation differences, food effects, dose escalation, precipitation, or another absorption question?
- Characterize the drug. Establish pKa, intrinsic solubility, permeability, and relevant solid-state properties.
- Characterize the formulation. Document particle size, dosage form, release characteristics, and relevant excipients.
- Measure dissolution behavior. Generate appropriate in vitro dissolution data where needed.
- Define GI physiology. Specify regional pH, fluid volumes, transit, and other relevant physiological conditions.
- Choose the dissolution model. Use an appropriate level of mechanistic detail.
- Represent precipitation where necessary. Include supersaturation and precipitation if the formulation or physicochemical properties make these processes relevant.
- Link dissolution to absorption. Couple dissolved drug to intestinal permeability and other absorption processes.
- Evaluate predictions. Compare predicted dissolution and systemic PK with observations.
- Perform sensitivity and uncertainty analysis. Identify parameters that materially affect conclusions.
- Use the model for simulation. Explore formulation, physiological, and dosing scenarios within the model's domain of applicability.
20. Key Takeaways
- Solubility describes how much drug can remain dissolved under specified conditions, whereas dissolution describes how quickly solid drug enters solution.
- Both dissolution and solubility can influence oral drug absorption and can be represented mechanistically in PBPK models.
- Drug solubility can depend strongly on pH, particularly for ionizable compounds.
- Particle size and surface area can influence the rate at which solid drug dissolves.
- The gastrointestinal tract presents changing pH, fluid volume, transit time, and solubilization conditions.
- Supersaturation can temporarily produce dissolved concentrations above equilibrium solubility, while precipitation can subsequently reduce dissolved drug.
- Dissolved drug is a dynamic pool governed by dissolution, precipitation, absorption, and other processes.
- BCS provides a useful framework for considering solubility and permeability, while PBPK can model these properties together with GI physiology and formulation behavior.
- Dissolution may be rate-limiting when solid drug enters solution more slowly than drug could otherwise be absorbed.
- Formulation changes such as micronization, amorphous dispersions, salts, and lipid-based systems can alter dissolution and solubility behavior.
- Mechanistic dissolution models require appropriate physicochemical, formulation, and physiological inputs.
- Model evaluation should consider both systemic PK and the mechanistic processes that the model is intended to represent.
- Sensitivity analysis can identify whether uncertain dissolution or solubility parameters materially affect predicted exposure.
- The purpose of dissolution PBPK modeling is to connect formulation and physicochemical properties to intestinal drug availability and ultimately to systemic exposure.
Where to Go Next
A natural progression is to study mechanistic absorption models in PBPK, including gastrointestinal compartment structure, intestinal permeability, transit, pH-dependent ionization, transporter effects, first-pass metabolism, and the integration of dissolution with absorption.
From there, more advanced topics include supersaturation and precipitation modeling, food-effect prediction, formulation PBPK, and the use of in vitro dissolution data to support in vivo predictions.
References
- Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research. 1995;12:413–420.
- Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. Journal of the American Chemical Society. 1897;19:930–934.
- Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics. 2000;50:47–60.
- Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption in humans. International Journal of Pharmaceutics. 1998;186:119–125.
- Jamei M, Turner D, Yang J, et al. Population-based mechanistic absorption modeling to predict the impact of physiological and formulation factors on oral drug absorption. Mechanistic absorption modeling literature.
- FDA. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Guidance for Industry.